{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T06:11:57Z","timestamp":1783836717726,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1038\/bmt.2015.322","type":"journal-article","created":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T14:45:59Z","timestamp":1451918759000},"page":"546-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study"],"prefix":"10.1038","volume":"51","author":[{"given":"S","family":"Afifi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N G","family":"Adel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Duck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Vanak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D J","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Lendvai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Korde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,4]]},"reference":[{"key":"BFbmt2015322_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BFbmt2015322_CR2","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.","journal-title":"N Engl J Med"},{"key":"BFbmt2015322_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","volume":"14","author":"I Pusic","year":"2008","unstructured":"Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045\u20131056.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015322_CR4","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","volume":"16","author":"P Wuchter","year":"2010","unstructured":"Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490\u2013499.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015322_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/bjh.12606","volume":"164","author":"G Milone","year":"2014","unstructured":"Milone G, Martino M, Spadaro A, Leotta S, Di Marco A, Scalzulli P et al. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol 2014; 164: 113\u2013123.","journal-title":"Br J Haematol"},{"key":"BFbmt2015322_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajh.22179","volume":"87","author":"GH Ozsan","year":"2012","unstructured":"Ozsan GH, Micallef IN, Dispenzieri A, Kumar S, Lacy MQ, Dingli D et al. Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. Am J Hematol 2012; 87: 1\u20134.","journal-title":"Am J Hematol"},{"key":"BFbmt2015322_CR7","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","volume":"21","author":"S Kumar","year":"2007","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035\u20132042.","journal-title":"Leukemia"},{"key":"BFbmt2015322_CR8","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/sj.leu.2405035","volume":"22","author":"A Mazumder","year":"2008","unstructured":"Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S . Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008; 22: 1280\u20131281.","journal-title":"Leukemia"},{"key":"BFbmt2015322_CR9","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/sj.leu.2405100","volume":"22","author":"H Paripati","year":"2008","unstructured":"Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22: 1282\u20131284.","journal-title":"Leukemia"},{"key":"BFbmt2015322_CR10","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.bbmt.2009.02.011","volume":"15","author":"U Popat","year":"2009","unstructured":"Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 718\u2013723.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015322_CR11","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","volume":"114","author":"S Kumar","year":"2009","unstructured":"Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009; 114: 1729\u20131735.","journal-title":"Blood"},{"key":"BFbmt2015322_CR12","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.20041385","volume":"201","author":"HE Broxmeyer","year":"2005","unstructured":"Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307\u20131318.","journal-title":"J Exp Med"},{"key":"BFbmt2015322_CR13","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767\u20134773.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015322_CR14","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","volume":"113","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720\u20135726.","journal-title":"Blood"},{"key":"BFbmt2015322_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/sj.bmt.1705908","volume":"41","author":"G Calandra","year":"2008","unstructured":"Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and\/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331\u2013338.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015322_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/bmt.2008.409","volume":"43","author":"CJ Fowler","year":"2009","unstructured":"Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K et al. Rescue from failed growth factor and\/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009; 43: 909\u2013917.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015322_CR17","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.bbmt.2009.08.005","volume":"15","author":"IN Micallef","year":"2009","unstructured":"Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G et al. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009; 15: 1578\u20131586.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015322_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/bmt.2010.54","volume":"46","author":"RF Duarte","year":"2011","unstructured":"Duarte RF, Shaw BE, Marin P, Kottaridis P, Ortiz M, Morante C et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011; 46: 52\u201358.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015322_CR19","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/bmt.2011.216","volume":"47","author":"K Hubel","year":"2012","unstructured":"Hubel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH et al. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant 2012; 47: 1046\u20131050.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015322_CR20","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/bmt.2012.60","volume":"47","author":"LJ Costa","year":"2012","unstructured":"Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD et al. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant 2012; 47: 1403\u20131408.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015322_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1600-0609.2010.01573.x","volume":"86","author":"E Jantunen","year":"2011","unstructured":"Jantunen E, Kuittinen T, Mahlamaki E, Pyorala M, Mantymaa P, Nousiainen T . Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol 2011; 86: 299\u2013304.","journal-title":"Eur J Haematol"},{"key":"BFbmt2015322_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/bmt.2010.128","volume":"46","author":"A D'Addio","year":"2011","unstructured":"D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356\u2013363.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015322_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.bbmt.2011.07.014","volume":"18","author":"I Attolico","year":"2012","unstructured":"Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2012; 18: 241\u2013249.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015322_CR24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ajh.23499","volume":"88","author":"VR Smith","year":"2013","unstructured":"Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G et al. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol 2013; 88: 754\u2013757.","journal-title":"Am J Hematol"},{"key":"BFbmt2015322_CR25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/bmt.2008.369","volume":"43","author":"MA Gertz","year":"2009","unstructured":"Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009; 43: 619\u2013625.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015322_CR26","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/sj.bmt.1702609","volume":"26","author":"L Meldgaard Knudsen","year":"2000","unstructured":"Meldgaard Knudsen L, Jensen L, Gaarsdal E, Nikolaisen K, Johnsen HE . A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant 2000; 26: 717\u2013722.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015322_CR27","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258\u20132266.","journal-title":"Cancer"},{"key":"BFbmt2015322_CR28","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/bmt.2012.281","volume":"48","author":"M Pozotrigo","year":"2013","unstructured":"Pozotrigo M, Adel N, Landau H, Lesokhin A, Lendvai N, Chung DJ et al. Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. Bone Marrow Transplant 2013; 48: 1033\u20131039.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015322_CR29","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.bbmt.2010.08.018","volume":"17","author":"P Shaughnessy","year":"2011","unstructured":"Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011; 17: 729\u2013736.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015322_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/bmt.2010.170","volume":"46","author":"LJ Costa","year":"2011","unstructured":"Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011; 46: 523\u2013528.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015322_CR31","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/bmt.2013.52","volume":"48","author":"F Awan","year":"2013","unstructured":"Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K et al. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant 2013; 48: 1279\u20131284.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2015322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015322","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:09:22Z","timestamp":1648062562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2015322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["BFbmt2015322"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.322","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,4]]},"assertion":[{"value":"13 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}